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Abstract
Background: Alternative treatments for visceral leishmaniasis (VL) are required in East Africa. Paromomycin sulphate (PM)
has been shown to be efficacious for VL treatment in India.
Methods: A multi-centre randomized-controlled trial (RCT) to compare efficacy and safety of PM (20 mg/kg/day for 21 days)
and PM plus sodium stibogluconate (SSG) combination (PM, 15 mg/kg/day and SSG, 20 mg/kg/day for 17 days) with SSG
(20 mg/kg/day for 30 days) for treatment of VL in East Africa. Patients aged 4–60 years with parasitologically confirmed VL
were enrolled, excluding patients with contraindications. Primary and secondary efficacy outcomes were parasite clearance
at 6-months follow-up and end of treatment, respectively. Safety was assessed mainly using adverse event (AE) data.
Findings: The PM versus SSG comparison enrolled 205 patients per arm with primary efficacy data available for 198 and 200
patients respectively. The SSG & PM versus SSG comparison enrolled 381 and 386 patients per arm respectively, with
primary efficacy data available for 359 patients per arm. In Intention-to-Treat complete-case analyses, the efficacy of PM was
significantly lower than SSG (84.3% versus 94.1%, difference=9.7%, 95% confidence interval, CI: 3.6 to 15.7%, p=0.002). The
efficacy of SSG & PM was comparable to SSG (91.4% versus 93.9%, difference=2.5%, 95% CI: 21.3 to 6.3%, p=0.198). End of
treatment efficacy results were very similar. There were no apparent differences in the safety profile of the three treatment
regimens.
Conclusion: The 17 day SSG & PM combination treatment had a good safety profile and was similar in efficacy to the
standard 30 day SSG treatment, suggesting suitability for VL treatment in East Africa.
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The parasitic disease visceral leishmaniasis (VL) has an
incidence of 500,000 new cases annually occurring primarily in
India, Bangladesh, Nepal, Sudan, and Brazil and is fatal if
untreated [1]. However, it is also an important disease in several
other East African countries, with an incidence rate of 30,000
cases per year and a mortality rate of 4,000 deaths per year [2,3].
VL treatment options in East Africa are primarily limited to the
antimonial sodium stibogluconate (SSG), which is efficacious, but
requires 4 weeks of hospitalization for daily intra-muscular
injections and has been associated with serious adverse events
such as cardiotoxicity; a concern in areas of HIV co-infection
[3,4,5]. In India, leishmania parasites have developed resistance to
SSG, with up to 65% of the population in the hyper endemic
region of Bihar being unresponsive [6,7]. SSG unresponsiveness is
emerging in East Africa and treatment with a combination of SSG
& PM may limit the spread of the emerging resistant strains of
leishmania parasites [8].
The efficacy of paromomycin sulphate (PM) monotherapy for
the treatment of VL has been demonstrated in India, where it is
now registered for the treatment of VL [9] and the safety and
efficacy of the combination of SSG and PM has been demon-
strated in trials in India and a small Kenyan study [10,11]. A large
case series of 4,263 VL patients carried out by Me ´decins sans
Frontie `res – Holland (MSF) in South Sudan showed that treating
patients with a combination of SSG & PM for 17 days yielded
better results than treating them with SSG alone: the initial cure
rate was 97% for SSG & PM for 17 days versus 92% for SSG
alone for 30 days [12].
For registration of PM and evaluation of the SSG & PM
combination therapy throughout East Africa, efficacy and safety
data were required from a Phase III trial. A multi-centre phase III
trial has been conducted in six clinical trials sites in 4 East Africa
countries (Ethiopia, Kenya, Sudan and Uganda). The trial started
in 2004 with three arms; SSG monotherapy (20 mg/kg/day for 30
days: reference arm), PM monotherapy (15 mg/kg/day for 21
days) and SSG & PM combination (SSG: 20 mg/kg/day, PM:
15 mg/kg/day both given for 17 days).
The aim was to compare safety and efficacy of PM monother-
apy and SSG & PM combination therapy with standard SSG
treatment. An interim analysis showed that the PM monotherapy
had an efficacy of ,50% parasite clearance 6 months after the end
of treatment in Sudan [13]. This arm was discontinued while a
separate dose-finding trial of alternative PM regimens was
conducted in Sudan [14]. The original Phase III trial was then
restarted with a higher PM monotherapy dose (20 mg/kg/day for
21 days), while the other two arms remained unchanged.
The objectives remained the same; to compare the efficacy and
safety of PM monotherapy and SSG & PM combination therapy
to SSG. The results of this trial are reported here.
Methods
Ethics statement
The trial was conducted in accordance with the Declaration of
Helsinki (2002 version) relating to the conduct of research on
human subjects and followed the International Committee on
Harmonization guidelines for the conduct of clinical trials. All trial
site personnel received training in Good Clinical Practice (GCP).
The relevant ethics committees from each country approved the
study and the details are listed in the attached supporting text
document. Patients and their legal guardians (if they were minors)
provided signed informed consent prior to being randomized to
the different treatment arms. GCP-trained monitors recruited
from all four participating countries regularly monitored the trial
at all sites.
Design
An open label, parallel-arm multi-centre individually random-
ized controlled trial.
Participants
Patients were enrolled from six clinical trials sites: Me ´decins
Sans Frontie `res (MSF) Holland treatment centre, Um el Kher,
Gedaref State, Sudan; Ministry of Health Hospital Kassab,
Gedaref State, Sudan; Gondar University Hospital, Amhara
State, Northern Ethiopia; Arba Minch Hospital, SNNPR state,
Southern Ethiopia; Centre for Clinical Research, Kenya Medical
Research Institute (KEMRI), Nairobi, Kenya; and Amudat
Hospital, Nakapiripirit Region, Uganda.
Inclusion and exclusion criteria have been described previously
[13]. Briefly, patients aged 4–60 years with parasitologically
confirmed VL were included, but patients with very severe VL or
those with contraindications were excluded (Figures 1 and 2).
Interventions
The three arms were SSG monotherapy (20 mg/kg/day for 30
days: reference arm), PM monotherapy (20 mg/kg/day for 21
days) and SSG & PM combination (SSG: 20 mg/kg/day, PM:
15 mg/kg/day both administered for 17 days).
Administration of PM (Gland Pharma, India) was intramuscular
(IM). SSG (Albert David, India) was administered IM, or
intravenous (IV) in Kenya. Patients requiring rescue medication
were given liposomal amphotericin B, (manufactured as Ambi-
someH, Gilead, USA) according to national dosage guidelines of
the participating countries. Patients were hospitalized for treat-
ment and weekly monitoring of clinical and biological parameters.
Follow-up visits were conducted 3 months and 6 months post end
of treatment (Figures 1 and 2).
Outcome Measures
The primary efficacy endpoint was definitive cure, defined as
parasite clearance from splenic, bone marrow or lymph node
tissue aspirates 6 months after the end of treatment. Any patient
Author Summary
Visceral leishmaniasis (VL) is a parasitic disease with about
500,000 new cases each year and is fatal if untreated. The
current standard therapy involves long courses, has
toxicity and there is evidence of increasing resistance.
New and better treatment options are urgently needed.
Recently, the antibiotic paromomycin (PM) was tested and
registered in India to treat this disease, but the same dose
of PM monotherapy evaluated and registered in India was
not efficacious in Sudan. This article reports the results of a
clinical trial to test the effectiveness of injectable PM either
alone (in a higher dose) or in combination with sodium
stibogluconate (SSG) against the standard SSG monother-
apy treatment in four East African countries—Sudan,
Kenya, Ethiopia and Uganda. The study showed that the
combination of SSG &PM was as efficacious and safe as the
standard SSG treatment, with the advantages of being
cheaper and requiring only 17 days rather than 30 days of
treatment. In March 2010, a WHO Expert Committee
recommended the use of the SSG & PM combination as a
first line treatment for VL in East Africa.
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had parasites detected at the 6-month assessment was considered a
treatment failure. The secondary efficacy endpoint was parasite
clearance from tissue aspirates at the end of treatment (SSG: day 31,
PM: day 22, SSG & PM: day18). Treatment failure at the end of
treatment was defined as death or receipt of rescue medication during
initial hospitalization or presence of parasites at end of treatment
necessitating rescue treatment. The presence of parasites at the end of
the treatment, subsequently cleared without need for rescue
treatment was considered a treatment success for primary outcome
(definitive cure at 6 months follow-up), but a treatment failure for
secondary outcome (cure at end of treatment). Slow responders were
defined as patients with detectable parasites at end of treatment and
parasite clearance at 6 months follow-up, without need for rescue
treatment at any time. Parasitology was performed and reported
according to an approved World Health Organization (WHO)
method [1]. The numbers of parasites in slide fields were counted
under oil emersion at 1006magnification and counts recorded.
Other Data Collection
Safety was evaluated based on the occurrence of adverse events
(AE), laboratory parameters (haematology and biochemistry),
electrocardiogram (ECG) readings, and audiometry. AEs were
classified according to the Medical Dictionary for Regulatory
Activities (MedDRA) version 10 [15]. A treatment emergent AE
(TEAE) was defined as an AE with onset between the first day of
treatment and 30 days after end of treatment.
ECGs were performed at all sites using a portable self-reporting
ECG machine (Cardiofax, Model ECG 9620, Nihon Kohden)
with patients resting supine on their beds. Trial physicians
reviewed tracings and reported any abnormality.
Post-kala-azar dermal Leishmaniasis (PKDL) was recorded
actively as an adverse event during patient follow-up or reported
directly by the patients in between follow-up dates.
Audiometric testing was performed at all trial sites except Um el
Kher using Voyager 522 Portable Diagnostic Audiometer
(Madsen, Taastrup, Denmark). In recruitment period 1, investi-
gators reported audiometric data as normal, clinically insignificant
or clinically significant [13]. In period 2, hearing levels were
recorded in detail for each ear at six frequencies. The following
definitions were used to measure abnormalities; 1) disabling hearing
impairment (DHI): an average hearing level, over frequencies 500,
1000, 2000, 4000 Hz, of $31 dB in both ears for those ,15 years
and $41 dB for those aged $15 years; 2) audiometric shift: a change
in hearing level from baseline of $25 dB at $1 threshold
frequency or $20 dB at $2 adjacent threshold frequencies.
Figure 1. CONSORT Patient Flowchart – SSG vs. PM. SSG, sodium stibogluconate; PM, paromomycin sulphate; SAE, serious adverse event; LTFU,
loss to follow-up; ITT, intention-to-treat; PP, per protocol. Patients included in the SSG (20 mg/kg/day for 30 days) vs. PM (20 mg/kg/day for 21 days)
arms;
a data from these patients were previously reported [14].
doi:10.1371/journal.pntd.0001674.g001
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accordance to national guidelines at screening.
Sample Size Determination
T h et r i a lw a sd e s i g n e dt oh a v e9 0 %p o w e r( b=0.1)todetect,at
t h e5 %s i g n i f i c a n c el e v e l( a=0.05), an absolute difference in efficacy
of 15% between PM and SSG and 10% between SSG & PM and
SSG regimens [16]. An 85% efficacy was assumed in the reference
arm and adjusting for 10% HIV co-infection and 10% loss to follow-
up at 6 months post end of treatment, it was estimated that 404 and
195 patients per arm were required for the respective comparisons.
Being HIV-positive was not an exclusion criteria but the original
protocol stated that there was to be a sufficient number of patients for
a subgroup analysis excluding HIV patients (if deemed necessary).
Randomization
As described at the end of the Introduction, recruitment and
randomisation was carried out during two periods. In the first
period, patients were randomised to SSG or SSG & PM
combination arms, as part of a randomisation into three arms.
Data from the third arm, a lower dosage regimen of PM found to be
ineffective are not included here. In the second period, randomisa-
tion continued into one of three arms; SSG, SSG & PM arms as per
period 1 and a PM monotherapy arm at a higher dosage regimen
than previously (see Introduction and Interventions sections.)
In recruitment period 2 (using the higher 20 mg/kg dose of PM),
randomization into 3 arms was continued until the desired sample
size was reached for the PM versus SSG comparison. Randomi-
zationwasthencontinued into oneoftwo arms (SSGorSSG& PM)
until reaching the sample size for the SSG versus SSG & PM
comparison. Um el Kher site participated in period 1 only and
Amudat site in period 2 only (during the two-arm randomization).
A computer-generated randomization list was produced with
stratification by centre and block sizes of 15 until recruitment in
the PM arm was completed, and block sizes of 10 thereafter.
Allocation was concealed using opaque, sequentially numbered
sealed envelopes. The randomization list and envelopes were
prepared and stored securely at the LEAP Data Centre, based at
the trial co-ordination centre in Nairobi.
Blinding of patients and investigators was not possible due to the
different treatment durations and additional placebo injections
were considered inappropriate.
Statistical Methods
Data were double-entered and validated in Epi-Info. Bespoke
query generation programs were developed using Stata software,
Figure 2. CONSORT Patient Flowchart – SSG vs. SSG&PM. SSG, sodium stibogluconate; PM, paromomycin sulphate; SAE, serious adverse
event; LTFU, loss to follow-up; ITT, intention-to-treat; PP, per protocol. Patients included in the SSG (SSG at 20 mg/kg/day for 30 days) vs. SSG & PM
combination (SSG at 20 mg/kg/day & PM at 15 mg/kg/day for 17 days) arms;
a patient was diagnosed with tuberculosis and was removed from the
study before the end of treatment;
b patient died from non-VL causes;
c patient with deviation also had a missing outcome value and was already
excluded from the ITT analysis.
doi:10.1371/journal.pntd.0001674.g002
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Baseline data were summarized using mean and standard
deviation (SD) or proportions where appropriate. Nutritional
status was classified as normal, underweight, or severely under-
weight according to WHO Child Growth Standards in those ,19
years and body mass index (BMI) in those $20 years [18].
Analysis Populations
For the SSG vs. PM comparison, patient data from randomisa-
tion during period 2 are included in this comparison. For the SSG
vs SSG & PM comparison, patient data from randomisation into
these arms in periods 1 and 2 are included in this comparison.
Efficacy data were analysed according to Intention-to-Treat
(ITT) and Per-Protocol (PP). The PP population excluded those
with pre-specified major protocol deviations (i.e. consent with-
drawal after taking a dose of study medication, receipt of under
70% or over 130% of the expected treatment dosage, or receipt of
alternative treatment to that of random allocation). Missing
efficacy data were handled in two ways for each analysis
population; complete-case analysis, where patients with missing
data were excluded and worst-case analysis, where missing
outcomes were considered treatment failures.
Efficacy is measured as the percentage of patients cured per
arm. The treatment effect is the difference in efficacy between
each test treatment (PM or SSG & PM) and the reference (SSG).
Unadjusted treatment effects were calculated with exact binomial
95% confidence intervals (CI). Adjusted treatment effects were
obtained using generalized linear models with a binomial
distribution and identity link function. To assess possible effects
of centre, age group (,18 years and $18 years) and recruitment
period on efficacy after accounting for treatment allocation,
regression models including treatment but with and without the
covariate of interest were compared using the likelihood ratio test
(LRT).
Treatment emergent adverse event (TEAE) rates were calcu-
lated as the number of TEAE, divided by the person-days at risk
for each arm, and comparisons made using rate ratios. The
treatment emergent period was defined as between day 1 of
treatment and 30 days after the pre-defined treatment period,
inclusive, therefore person-time at risk was as follows; SSG arm:
60 days, PM: 51 days, SSG & PM: 47 days. An adverse drug
reaction was defined where an investigator recorded a probable,
possible or unlikely relationship between the AE and study drug
for VL.
Table 1. Baseline Data.
SSG PM SSG & PM
N=386 N=205 N=381
Centre Ethiopia: Gondar, n (%) 60 (15.5) 15 (7.3) 60 (15.8)
Ethiopia: Arba Minch, n (%) 45 (11.7) 15 (7.3) 45 (11.8)
Kenya: KEMRI, n (%) 71 (18.4) 35 (17.1) 70 (18.4)
Sudan: Um el Kher, n (%) 30 (7.8) - 30 (7.9)
Sudan: Kassab, n (%) 167 (43.3) 140 (68.3) 165 (43.2)
Uganda: Amudat, n (%) 13 (3.4) - 11 (2.9)
Age Mean (SD) 15.3 (9.3) 15.3 (9.9) 16.1 (9.4)
Age 4–17 years
a, n (%) 259 (67.1) 143 (69.8) 246 (64.6)
Age $18 years
a, n (%) 127 (32.9) 62 (30.2) 135 (35.4)
Sex Female, n (%) 105 (27.2) 80 (39.4) 108 (28.4)
Male, n (%) 281 (72.8) 125 (61.0) 273 (71.6)
Anthropometry
b Weight (Kg) 33.5 (14.5) 33.1 (15.5) 34.2 (14.7)
Height (m) 1.4 (0.2) 1.4 (0.2) 1.5 (0.2)
Vital Signs
b Body temperature (uC) 38.1 (1.1) 38.4 (1.0) 38.2 (1.1)
Heart Rate (beats/min) 108.2 (16.1) 111.7 (14.4) 107.3 (15.9)
Systolic BP (mm Hg) 96.3 (11.2) 96.1 (10.4) 97.3 (11.1)
Diastolic BP (mm Hg) 61.5 (8.4) 59.8 (7.9) 61.6 (8.1)
Organ Size
b Spleen Size (cm) 8.1 (5.0) 7.7 (5.0) 8.0 (4.8)
Liver Size (cm) 3.0 (2.6) 2.8 (2.7) 3.0 (2.6)
Nutritional Status
c Severely underweight, n (%) 61 (15.8) 60 (29.3) 105 (27.5)
Underweight, n (%) 167 (43.3) 62 (30.2) 140 (36.8)
Normal, n (%) 156 (40.4) 78 (38.6) 134 (35.2)
Obese/overweight, n (%) 2 (0.5) 4 (2.0) 2 (0.5)
HIV Status
d HIV-positive, n (%) 5 (1.3) 0 (0) 9 (2.4)
SSG=sodium stibogluconate (20 mg/kg/day for 30 days); PM=paromomycin sulphate (20 mg/kg/day for 21 days); SSG & PM Combination treatment (SSG at 20 mg/
kg/day plus PM at 15 mg/kg/day for 17 days);
aPatients 4–17 years old were classified as children and patients 18–60 years old were classified as adults.
bThese are presented as mean (SD).
cClassification based on World Health Organization child growth standards in patients #19 years or using body mass index in those $20 years.
d340 out of 386, 203 out of 205, and 335 out of 381 patients were tested for HIV in the SSG, PM and SSG & PM arms respectively.
doi:10.1371/journal.pntd.0001674.t001
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Patient Population
The study was initiated in November 2004 and was
completed in January 2010. A total of 2862 patients were
screened for entry into the trial. Of these, 1755 were excluded
(Figures 1 and 2), mainly due to negative parasitology. For the
PM monotherapy versus SSG comparison, 205 patients per arm
were recruited during period 2 (Figure 1). The total sample size
for the SSG versus SSG & PM comparison was 386 patients in
the SSG arm and 381 for SSG & PM (Figure 2): 135 patients
per arm from period 1; 251 and 246 per arm respectively, from
period 2.
Treatment arms were balanced for both comparisons with
respect to demographic characteristics, vital signs, and physical
measurements (combined arm data shown in Table 1). There were
more male than female patients and more than 65% of patients
were under the age of 18 years. All biological data except for
nutritional status were balanced between arms at baseline; more
patients in the PM and SSG & PM arms were classified as severely
underweight but, overall combined percentages of underweight and
severely underweight were balanced by arm. Overall, for all
recruited patients, the HIV co-infection frequency was 1.4% (95%
CI: 0.8–2.4%).
Compliance
In the population analysed for the SSG versus PM comparison
(n=205 per arm), one patient in each arm did not receive the
correct treatment allocation (Figure 1). Two patients in the PM
arm withdrew consent after 4 and 6 days of treatment. For the
SSG versus SSG & PM analysis population, three (0.8%) patients
in the SSG arm and eight (2.0%) in the SSG & PM arm received a
partial or incorrect dose (Figure 2). One SSG & PM patient
withdrew consent after 6 days on treatment. Patients who had
their 6-month follow-up at or before 4.5 months after the end of
treatment were considered lost to follow-up since these visits were
too early to assess definitive cure. For the SSG versus PM
comparisons, outcome data for one (0.5%) patient in the SSG arm
and two (1.0%) in the PM arm were considered missing. For the
SSG versus SSG & PM comparison, outcome data for 13 (6.5%)
SSG patients and nine (2.5% )SSG & PM patients were treated as
missing data based on early follow-up. Data for patients whose
primary endpoint assessment was later than 6 months were
included in the analysis.
Efficacy: PM versus SSG
Efficacy in the SSG (reference) arm was 94% at 6 months after
the end of treatment and 84% in the PM arm, according to the
ITT complete-case population. All pre-specified primary endpoint
analyses (ITT complete-case and worst-case, PP complete-case
and worst-case) suggest that the efficacy of PM monotherapy was
significantly lower than SSG - up to 17% less efficacious (Table 2).
There were negligible differences in estimates of treatment effect
and corresponding 95% CIs in these four pre-specified analyses.
After adjustment for arm, efficacy did not differ between adults
($18 years) and children (p.0.4 for both ITT and PP complete-
case analyses).
There were 8 (4.0%) slow responders of the 198 ITT complete-
case PM patient population at 6 months after the end of treatment
and none in the SSG arm. Secondary endpoint treatment effects
measured at the end of treatment were again very similar to 6
months primary endpoint data (Table 2).
Table 2. Paromomycin (PM) monotherapy versus Sodium Stibogluconate (SSG): Efficacy Data.
Number of patients analyzed
a Number (%) cured Treatment effect
b (95% CI), p-value
c
Six months follow-up:
ITT: Complete Case Analysis
d
SSG: N=200 188 (94.0) 9.7 (3.6–15.7), p=0.002
PM: N=198 167 (84.3)
PP: Complete Case Analysis
d
SSG: N=199 188 (94.5) 10.2 (4.2–16.2), p=0.001
PM: N=197 166 (84.3)
ITT: Worst Case Analysis
e
SSG: N=205 188 (91.7) 10.2 (3.7–16.8), p=0.002
PM: N=205 167 (81.5)
PP: Worst Case Analysis
e
SSG: N=204 188 (92.2) 10.8 (4.3–17.3), p=0.001
PM: N=204 166 (81.4)
End of Treatment:
ITT: Complete Case Analysis
d
SSG: N=205 197 (96.1) 9.9 (4.4–15.3), p,0.001
PM: N=203 175 (86.2)
CI=confidence interval, ITT=Intention-to-Treat, PP=Per-Protocol.
a205 patients were originally recruited to the PM arm, 386 to the SSG arm.
bTreatment effect: difference in efficacy between SSG and PM, percent scale with exact binomial 95% CI. Adjustment for centre was not possible due to only one failure
in one centre.
cp-value from likelihood ratio test comparing binomial regression models with and without treatment.
dComplete-case analysis: patients with missing outcome data excluded from analysis.
eWorst-case analysis: missing outcomes assumed to be treatment failures.
doi:10.1371/journal.pntd.0001674.t002
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In ITT complete-case primary endpoint analyses, the efficacy of
SSG was 94% and for SSG & PM, 91% (Table 3). No difference in
efficacy was noted between treatments. After adjusting for arm, no
additional differences in efficacy were found between centres, age
groups or recruitment periods (p.0.1, Table 3).
Worst-case analyses in the ITT and PP populations did suggest
some additional variation by centre, age group and period after
accounting for arm; due to some imbalance in losses to follow-up
by age group and centre. However, treatment effects and
corresponding 95% CIs were very similar in all four pre-specified
primary endpoint analyses (Table 3).
In the SSG arm, 3 (0.8%) of 359 ITT complete-case analysis
patients were slow responders, compared to 7 (1.9%) of the 359
SSG & PM patients. End of treatment secondary endpoint efficacy
data were in agreement with primary endpoint data (Table 3).
Safety
The proportion of patients with SAE and non-serious TEAEs
was similar in comparisons of both test treatment regimens to SSG
(Table 4). Approximately 3% of patients in each arm in each
comparison experienced an SAE deemed to be an adverse drug
reaction (Table 4). One death occurred duringthe treatment period
in each arm in the SSG versus PM comparison. In the SSG & PM
versus SSG comparison, there were 3 deaths during initial
hospitalization and a death of unknown cause during follow-up in
the SSG arm. In the SSG & PM arm, there was a treatment period
death and an unrelated death during follow-up (Tables 4 and 5). Of
the 5 cases of renal impairment, 3 led to death, whilst 2 resolved
after some time. Patients were withdrawn from treatment in all
cases. Important cardiac events occurred in two patients: one in the
SSG-PM arm and one in the SSG arm. In the former, a long QT
interval appeared on Day 7, leading to treatment withdrawal. The
long QT interval resolved 3 days later. In the second case, the
patient died due to cardiotoxicity on Day 11 of treatment.
Rates and rate ratios, adjusted for centre, in both comparisons
show no difference in safety based on analysis of TEAEs; adjusted
rate ratio between the SSG and PM arm: 1.13, (95% CI: 0.93 to
1.38, p=0.225) and between the SSG and Combination arms:
1.01, (95% CI: 0.88 to 1.17, p=0.993). All of the non-fatal SAEs
in the SSG and Combination arms resolved by the 6-month
follow-up and all except one (pulmonary tuberculosis) in the PM
arm resolved by the 6-month follow-up.
Treatment emergent adverse drug reactions (TEADRs) occur-
ring in $10% of patients in the PM arm were injection site pain
(13.2%), increase in aspartate aminotransferase (10.7%), and
epistaxis (13.2%). In the subset of SSG patients analysed in the
SSG versus PM comparison, TEADRs occurring in $10% of
patients were aspartate aminotransferase increases (10.2%) and
epistaxis (11.2%). For the population in the SSG versus
Combination arms, no TEADR occurred in $10% of patients
in the larger group of SSG patients. In the Combination arm, the
most common TEADRs were injection site pain (17.3%) and
increases in aspartate aminotransferase (10.5%).
Two patients in the Combination arm and one in the SSG arm
had abnormal ECG findings that were considered clinically
significant at end of treatment. These were, respectively, QT-wave
inversion in V1–V4, arrhythmia and QT interval prolongation,
which had normalized by 6 months follow-up.
Table 3. Sodium Stibogluconate (SSG) & Paromomycin (PM) versus SSG: Efficacy Data.
Number of patients analyzeda Number (%)cured
Treatment effect
b
(95% CI), p-value
c Centre p-value
d Age p-value
d Period p-value
d
Six months follow-up:
ITT: Complete Case Analysis
e
SSG: N=359 337 (93.9) 2.5 (21.3–6.3) 0.337 0.122 0.112
SSG & PM: N=359 328 (91.4) p=0.198
PP: Complete Case Analysis
e ,
SSG: N=357 336 (94.1) 2.8 (21.1–6.6) 0.286 0.080 0.064
SSG & PM: N=347 317 (91.4) p=0.157
ITT: Worst Case Analysis
f
SSG: N=386 337 (87.3) 1.2 (23.6–6.0) ,0.001 0.008 ,0.001
SSG & PM: N=381 328 (86.1) p=0.620
PP: Worst Case Analysis
f
SSG: N=383 336 (87.7) 1.8 (23.0–6.7) ,0.001 0.007 ,0.001
SSG & PM: N=369 317 (85.9) p=0.460
End of Treatment:
ITT: Complete Case Analysis
e ---
SSG: N=385 366 (95.1) 1.9 (21.4–5.3)
SSG & PM: N=378 352 (93.1) p=0.254
CI=confidence interval, ITT=Intention-to-Treat, PP=Per-Protocol.
a381patients were originally recruited to the SSG&PM arm, 386 to the SSG arm.
bTreatment effect: difference in efficacy between SSG and SSG & PM combination treatment, percent scale with exact binomial 95% CI.
cp-value from likelihood ratio test comparing binomial regression models with and without treatment.
dp-value from likelihood ratio test comparing binomial regression models with and without factor of interest, after adjustment for treatment allocation.
eComplete-case analysis: patients with missing outcome data excluded from analysis.
fWorst-case analysis: missing outcomes assumed to be treatment failures.
doi:10.1371/journal.pntd.0001674.t003
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developed PKDL in the SSG arm and 18 (8.9%) out of 203
patients randomised to PM. In the SSG vs SSG & PM comparison,
48 (12.4%) out of 386 patients in the SSG group and 23 (6.1%) out
of 380 patients in the SSG-PM group developed PKDL. Two
patients were given SSG for PKDL during their three months
follow-up visit. DHI was reported in one patient in the PM and
one patient in the Combination arm at the end of treatment, both
of which resolved by the 6-month follow-up. None of the patients
in the SSG arm had DHI. Thirty-six patients had audiometric
shift at end of treatment (11 patients in the SSG arm, nine in the
PM arm, and 16 in the SSG & PM arm). Audiometric shifts had
still not resolved at the 6-month follow-up in three of the SSG,
four of the PM and eight of the Combination patients.
Discussion
This phase III GCP-compliant RCT investigated the safety and
efficacy of PM both as monotherapy (20 mg/kg/day for 21 days)
and as short course treatment in combination with SSG (PM at
15 mg/kg/day and SSG at 20 mg/kg/day for 17 days) for VL
treatment in four East African countries, with the ultimate goal of
determining if the SSG & PM combination treatment has
acceptable safety and efficacy profiles to support its introduction
in the region.
Study Limitations
Definitive cure at six months follow-up in patients treated with
SSG or SSG & PM was comparable with greater than 90%
efficacy, despite PM monotherapy having significantly lower
efficacy (84% cured) compared to SSG. Efficacy of the 20 mg/
kg/day PM monotherapy at the 33% higher dose used in this
study was better than that of the 15 mg/kg/day dose used earlier
[13] (6-month cure rate of 84% vs. 64%), and is consistent with the
dose-finding study conducted by the authors in Sudan [14].
However, the efficacy at this higher dose was still lower than that
of SSG alone. By contrast, studies performed in India had shown
that the efficacy of PM was consistently .90% at 15 and 20 mg/
kg day for 21 days [19,20], with PM showing better efficacy than
SSG (20 mg/kg/day for 30 days) in the Jha et al. study [19] and
non-inferior efficacy compared with amphotericin (1 mg/kg/day
every 2 days for 30 days) in the Sundar et al. study [20].
Pharmacological differences in the East African and Indian
populations that may explain these results were explored and will
be reported separately. Geographical variation in efficacy of PM
seen for the lower daily dose (15 mg/kg) was not apparent in this
study with the higher daily dosage (20 mg/kg), though it must be
noted that sufficient numbers of patients were not enrolled at all
sites to perform a by-site analysis.
Secondary endpoints were performed at different times for each
of the treatments (day 18 for the combination, day 22 for PM and
day 31 for SSG), assumed comparable by design but potentially
leading to bias in clinical and parasitological evaluations.
Similarly, lack of blinding also may have led to bias in reporting,
especially once lack of PM efficacy at the 15 mg/kg dose was
suspected. As numerous sites and countries were involved,
differentiation of reporting, particularly of adverse events was
possible. Nonetheless, using a standard primary endpoint at 6
months and an objective measurement of efficacy based on
parasitology, high rates of follow up were achieved. This is
reflected in the relatively robust and comparable findings of the
ITT, per protocol, complete case and worst case analyses.
The trial was powered to evaluate efficacy at the primary
endpoint of 6 months follow-up and had limited power to detect
differences in safety outcomes. However, almost identical rates of
TEAEs and proportions of patients with adverse drug reactions
were observed in patients treated with each regimen in the trial.
The study was not powered to perform a subgroup analysis in
HIV-positive patients assuming a 10% co-infection rate and HIV
positive patients were not excluded. HIV co-infection was lower
than expected, which may be due to the relatively small number of
patients enrolled in Northern Ethiopia, where up to 35% co-
infection had previously been reported [21]. In this study, 3 out of
5 and 5 out of 9 HIV co-infected patients had parasite clearance at
6 months after treatment with SSG and SSG & PM respectively. It
was not possible to conclude on the difference in toxicity of either
treatment among HIV co-infected patients.
Almost all of the SAEs that emerged in the three arms during
treatment had resolved by the 6-month follow-up. There was no
evidence of any new or important safety events, in either the PM
or Combination arm. Although slightly more audiometric shifts
remained at the 6-month follow in the PM and SSG & PM arms
compared with the SSG arm, the trial was not powered to test for
differences. With a larger sample size, percentages of patients
with shifts remaining may have been balanced. Although not
statistically significant, three deaths in the SSG arm were
considered to be treatment-related (cardiotoxicity and renal
disorders), whereas there were no treatment-related deaths in the
Combination arm.
Table 4. Serious and non-serious adverse events occurring
during the study.
SSG PM
a SSG & PM
a
N=386 N=205 N=381
N (%) of patients with at
least one AE
At any time 271 (70.2) 126 (61.5) 251 (65.9)
TEAEs
b 237 (61.4) 107 (52.2) 207 (54.3)
N (%) of patients with
an SAE
c
Total 17 (4.4) 8 (3.9) 16 (4.2)
TEAEs
b 14 (3.6) 7 (3.4) 16 (4.2)
Adverse drug reactions
d 10 (2.6) 6 (2.9) 13 (3.4)
Deathse 4 (1.0) 1 (0.5) 2 (0.5)
Total number of all TEAEs
recorded
445 192 348
Total person-days at risk
f 23160 10363 17866
TEAE Rate 0.019 0.019 0.019
SSG=sodium stibogluconate; PM=paromomycin sulphate; SSG &
PM=combination treatment;
AE, adverse event; SAE, serious adverse event; TEAE, treatment emergent
adverse event;
aThere were two consent withdrawals in the PM arm (after 4 and 6 days on
treatment) and 1 withdrawal in the SSG & PM arm (after 6 days on treatment) -
data were therefore collected only up to the day of withdrawal for these
patients.
bTreatment emergent adverse event is defined as onset being between day 1 of
treatment and 30 days post end of treatment, inclusive.
cNo patient experienced more than one SAE.
dAdverse drug reaction is defined as any adverse event the investigator
recorded as having a probable, possible or unlikely relationship to the study
drug.
eCause of deaths were as follows: SSG: unknown (1), Acute Renal Failure (2),
cardiotoxicity (1); PM: VL; SSG & PM: Pericarditis tuberculosis (1), malaria (1).
fPerson-days at risk is defined as the treatment period per study drug regimen
plus an additional 30 days post end of treatment.
doi:10.1371/journal.pntd.0001674.t004
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These results, together with those of a retrospective comparison
of a 17 day regimen of SSG & PM versus 30 days of SSG alone
carried out among 4,263 primary VL patients in South Sudan [12]
support the use of a shorter course Combination therapy for VL in
East Africa, which would be consistent with the long-term goal of
reducing reliance on SSG monotherapy.
The reduced duration of treatment with the Combination
compared with SSG (17 versus 30 days) will also reduce burden on
hospitals and patients and other associated costs. The cost of drugs
Table 5. All Serious Adverse Events (non-related events and related adverse drug reactions) by System Organ Class (bold) and
Preferred Term according to MedDRA.
System organ class and preferred MedDRA term SSG PM
b SSG & PM
d
N=386 N=205 N=381
NR SADR NR SADR NR SADR
Cardiac disorders 0 1 0 0 0 0
Cardiotoxicity 0 1 0 0 0 0
Gastrointestinal disorders 1 1 0 0 0 1
Pancreatitis acute 0 0 0 0 0 1
Pancreatitis 0 1 0 0 0 0
Peritoneal haemorrhage 1 0 0 0 0 0
General disorders and administrative site conditions 1 0 0 0 0 0
Death
a 10 00 00
Hepatobiliary disorders 0 0 0 0 0 1
Hepatic function abnormal
b 00 00 01
Immune system disorders 2 0 0 0 0 0
Anaphylactic shock 2 0 0 0 0 0
Infections and Infestations 1 2 2 2 3 0
Abdominal sepsis
c 01 00 00
Malaria
c 01 00 10
Hepatitis A 0 0 0 1 0 0
Herpes Zoster 1 0 0 0 0 0
Otitis Media 0 0 1 0 0 0
Pericarditis tuberculosis 0 0 0 0 1 0
Pneumonia 0 0 0 0 1 0
Pulmonary tuberculosis 0 0 1 0 0 0
Visceral leishmaniasis 0 0 0 1 0 0
Investigations 0 4 0 2 0 9
Alanine amino transferase increased (ALT only) 0 0 0 0 0 1
Blood alkaline phosphatase increased (ALP only) 0 0 0 0 0 1
Blood amylase increased 0 1 0 0 0 0
Electrocardiogram QT prolonged 0 0 0 0 0 1
Hepatic enzymes increased (bilirubin, ALT/AST/ALP) 0 1 0 1 0 3
Transaminases increased (ALT/AST) 0 2 0 1 0 3
Nervous system disorders 0 0 0 1 0 0
Febrile convulsion 0 0 0 1 0 0
Renal and urinary disorders 0 2 0 1 0 2
Renal impairment 0 2 0 1 0 2
Reproductive system and breast disorders 1 0 0 0 0 0
Priapism 1 0 0 0 0 0
Respiratory, thoracic and mediastinal disorders 1 0 0 0 0 0
Epistaxis 1 0 0 0 0 0
MedDRA, Medical Dictionary of Regulatory Activities; SSG, sodium stibogluconate (20 mg/kg/day for 30 days); PM paromomycin sulphate (20 mg/kg/day for 21 days);
SSG & PM (SSG 20 mg/kg/day & PM at 15 mg/kg/day for 17 days); NR, non-related Serious Adverse Events; SADR, Serious Adverse Drug Reaction.
aDeath due to an unknown cause.
bRaised bilirubin/jaundice.
cAbdominal sepsis and malaria were considered as unlikely related to the drug by the investigators.
d2 PM patients withdrew consent after 4 and 6 days on treatment and 1 SSG & PM patient after 6 days on treatment, no SAE reported prior to withdrawal.
doi:10.1371/journal.pntd.0001674.t005
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SSG (44US$ versus 55.8 US$ respectively for a patient weighing
35 kg) [1]. Finally, the potential risk of development of parasite
resistance to the treatment could be reduced.
In conclusion, our results show that SSG & PM combination
treatment has comparable efficacy and safety profiles to
conventional SSG monotherapy in a Phase III setting, and
support its introduction for treatment of primary VL in East
Africa.
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